Literature DB >> 10404806

Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency.

J C ter Maaten1, H de Boer, O Kamp, L Stuurman, E A van der Veen.   

Abstract

Short term GH replacement therapy has been shown to improve body composition and exercise capacity. It is not yet known whether GH replacement remains beneficial over the long term. We assessed the effects of long term GH replacement on body composition, bone mineral density, and cardiac function. Thirty-eight men with childhood-onset GH deficiency were studied for a period of 3-5 yr. Measurements included anthropometry, computed tomographic scanning of abdomen and upper leg, bone densitometry, echo cardiography, and bicycle ergometry. The initial GH dose of 1-3 IU/m2 x day (9-27 microg/kg) was gradually tapered to 1.30+/-0.38 IU/m2 x day (11 g/kg), aiming at physiological insulin-like growth factor I levels. During the study, leg muscle mass progressively increased by 28.7% (P<0.001). Subcutaneous and intraabdominal fat decreased by 30.9% and 46.0%, respectively, after 1 yr (both P<0.001), but demonstrated a partial regain thereafter. Bone mineral density at the lumbar spine, femoral neck, and trochanter gradually increased by 9.6%, 11.1%, and 16.2%, respectively (all P<0.001). Left ventricular mass exceeded baseline values by 14.1% after 1 yr (P<0.001), but returned to pretreatment values thereafter. Stroke volume and cardiac output increased by 16.3% (P = 0.002) and 33.4% (P<0.001), respectively. Maximal work load increased from 189+/-30 to 232+/-41 watts (P<0.001). Thus, long term GH replacement is safe and beneficial. It improves cardiac performance without inducing left ventricular hypertrophy and progressively increases bone mineral density.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404806     DOI: 10.1210/jcem.84.7.5851

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Transitioning of children with GH deficiency to adult dosing: changes in body composition.

Authors:  Vi Thuy Nguyen; Madhusmita Misra
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 3.  The cardiovascular system in growth hormone excess and growth hormone deficiency.

Authors:  G Lombardi; C Di Somma; L F S Grasso; M C Savanelli; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

4.  Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study.

Authors:  Mikkel Andreassen; Jens Faber; Andreas Kjaer; Claus Leth Petersen; Lars Østergaard Kristensen
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

5.  The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency.

Authors:  Anton Dlesk; Gabriel Kamenský; Ivica Lazúrová; Martin Kužma; Juraj Payer
Journal:  Wien Klin Wochenschr       Date:  2014-07-01       Impact factor: 1.704

6.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

7.  Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency.

Authors:  Maria Claudia Peixoto Cenci; Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Vera Aleta Mansur; Jaime Gold; Eduardo Michmacher; Mario Vaisman; Flávia Lúcia Conceição
Journal:  Pituitary       Date:  2009-04-24       Impact factor: 4.107

Review 8.  Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives.

Authors:  Y Rolland; G Abellan van Kan; A Bénétos; H Blain; M Bonnefoy; P Chassagne; C Jeandel; M Laroche; F Nourhashémi; P Orcel; F Piette; C Ribot; P Ritz; C Roux; J Taillandier; F Trémollières; G Weryha; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-05       Impact factor: 4.075

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

10.  The effect of recombinant human growth hormone therapy on left-ventricular chamber size and function in children with growth hormone deficiency.

Authors:  Ihsan Esen; Ilker Cetin; Fatma Demirel; Filiz Ekici
Journal:  Pediatr Cardiol       Date:  2013-06-13       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.